The Journal of Heart and Lung Transplantation
Volume 25, Issue 3 , Pages 298-301 , March 2006

Percutaneous Coronary Interventions With Stents in Cardiac Transplant Recipients

Received 25 April 2005 ,Revised 16 July 2005 ,Accepted 11 September 2005.

References 

  1. Taylor DO , Edwards LB , Boucek MM , et al.   The registry of the International Society for Heart and Lung Transplantation (twenty-first official adult heart transplant report—2004) . J Heart Lung Transplant . 2004;23:796–803
  2. Redonnet M , Tron C , Koning R , et al.   Coronary angioplasty and stenting in cardiac allograft vasculopathy following heart transplantation . Transplant Proc . 2000;32:463–465
  3. Costanzo MR , Naftel DC , Pritzker MR , et al.   Heart transplant coronary artery disease detected by coronary angiography (a multi-institutional study of pre-operative donor and recipient risk factors) . J Heart Lung Transplant . 1998;17:744–753
  4. Weis M , Von Scheidt W . Cardiac allograft vasculopathy (a review) . Circulation . 1997;96:2069–2077
  5. Melnick JL , Adam E , Debakey ME . Possible role of cytomegalovirus in atherogenesis . JAMA . 1990;263:2204–2207
  6. Johnson DE , Alderman EL , Schroeder JS , et al.   Transplant coronary artery disease (histopathologic correlations with angiographic morphology) . JAMA . 1991;17:449–457
  7. Heublein B , Pethig K , Maab C , Wahlers T , Haverich A . Coronary artery stenting in allograft vascular disease . Am Heart J . 1997;134:930–938
  8. Schroeder JS , Gao SZ , Hunt SA , Stinson EB . Accelerated graft coronary artery disease (diagnosis and prevention) . J Heart Lung Transplant . 1992;11(suppl):S258–S265
  9. Kobashigawa JA , Katznelson S , Lakes H , et al.   Effect of pravastatin on outcomes after cardiac transplantation . N Engl J Med . 1995;333:621–627
  10. Wenke K , Meiser B , Thiery J , et al.   Simvastatin reduces graft vessel disease and mortality after heart transplantation (a four- year randomized trial) . Circulation . 1997;96:1398–1402
  11. Paul LC . Calcium channel blockers and angiotensin-converting enzyme inhibitors in the prevention of graft vasculopathy . J Heart Lung Transplant . 2000;19:409–413
  12. Halle AA , DiSciascio G , Massin E , et al.   Coronary angioplasty, atherectomy, and bypass surgery in cardiac transplant recipients . JAMA . 1995;26:120–128
  13. Schnetzler B , Drobinski G , Dorent R , et al.   The role of percutaneous transluminal coronary angioplasty in heart transplant recipients . J Heart Lung Transplant . 2000;19:557–565
  14. Wong PMT , Piamsomboon C , Mathur A , et al.   Efficacy of coronary stenting in the management of cardiac allograft vasculopathy . Am J Cardiol . 1998;82:239–241
  15. Doshi AA , Rogers J , Kern MJ , Hauptman PJ . Effectiveness of percutaneous coronary intervention in cardiac allograft vasculopathy . Am J Card . 2004;93:90–92
  16. Aranda JM , Pauly DF , Kerensky RA , et al.   Percutaneous coronary intervention versus medical therapy for coronary allograft vasculopathy one center’s experience . J Heart Lung Transplant . 2002;21:860–866
  17. Fischman DL , Leon MB , Baim DS , et al.   A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease . N Engl J Med . 1994;331:496
  18. Serruys PW , de Jaegere P , Kiemeneij F , et al.   A comparison of balloon expandable stent implantation with balloon angioplasty in patients with coronary artery disease . N Engl J Med . 1994;331:489
  19. Kimmel SE , Localio AR , Krone RJ , Laskey WK  Registry committee of the Society for Cardiac Angiography and Interventions . The effects of contemporary use of coronary stents on in-hospital mortality . JAMA . 2001;37:499
  20. Banza RL , Zoghbi GJ , Tallaj J , et al.   Palliation of allograft vasculopathy with transluminal angioplasty (a decade of experience) . JAMA . 2004;43:1973–1981
  21. Moses JW , Leon MB , Popma JL . Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery . N Engl J Med . 2003;349:1315
  22. Stone GW , Ellis SG , Cox DA , et al.   A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease . N Engl J Med . 2004;350:221
  23. Eisen HJ , Tuzcu EM , Dorent R , et al.   Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients . N Engl J Med . 2003;349:847
  24. Mancini D , Pinney S , Burkhoff D , et al.   Use of rapamycin slows progression of cardiac transplantation vasculopathy . Circulation . 2003;108:48
  25. Keogh A , Richardson M , Ruygrok P , et al.   Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years (a randomized clinical trial) . Circulation . 2004;110:2694
  26. Mehra MR , Ventura HO , Uber PA , Scott RL , Park MH . Is all intimal proliferation created equal in cardiac allograft vasculopathy? The quantity–quality paradox . J Heart Lung Transplant . 2003;22:118–123
  27. Ruygrok PN , Farb A , Coverdale HA , Gibbs HC , Virmani R . Histology of in-stent restenosis in a transplanted Heart . J Heart Lung Transplant . 2004;23:143–146

PII: S1053-2498(05)00701-1

doi: 10.1016/j.healun.2005.09.016

The Journal of Heart and Lung Transplantation
Volume 25, Issue 3 , Pages 298-301 , March 2006

Article Tools